Research Progress of the CXCR4 Mechanism in Alzheimer's Disease

Overview

Journal Ibrain

Specialty Neurology

Date 2023 Oct 3

PMID 37786419

Authors

Qiu-Lin Wang

Chang-Le Fang

Xue-Yan Huang

Lu-Lu Xue

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a degenerative brain disease with complex clinical manifestations and pathogeneses such as abnormal deposition of beta-amyloid protein and inflammation caused by the excessive activation of microglia. CXC motif chemokine receptor type 4 (CXCR4) is a type of G protein-coupled receptor that binds to CXC motif ligand 12 (CXCL12) to activate downstream signaling pathways, such as the Janus kinase/signal transducer and activator of transcription and the renin-angiotensin system (Ras)/RAF proto-oncogene serine (Raf)/mitogen-activated protein kinase/extracellular-regulated protein kinase; most of these signaling pathways are involved in inflammatory responses. CXCR4 is highly expressed in the microglia and astrocytes; this might be one of the important causes of inflammation caused by microglia and astrocytes. In this review, we summarize the mechanism and therapeutics of AD, the structures of CXCR4 and the CXCL12 ligand, and the mechanisms of CXCR4/CXCL12 that are involved in the occurrence and development of AD. The possible treatment of AD through microglia and astrocytes is also discussed, with the aim of providing a new method for the treatment of AD.

Citing Articles

The role of CXCL12/CXCR4/CXCR7 axis in cognitive impairment associated with neurodegenerative diseases.

Sarallah R, Jahani S, Khaboushan A, Moaveni A, Amiri M, Zolbin M Brain Behav Immun Health. 2025; 43():100932.

PMID: 39834554 PMC: 11743895. DOI: 10.1016/j.bbih.2024.100932.

MORE: a multi-omics data-driven hypergraph integration network for biomedical data classification and biomarker identification.

Wang Y, Wang Z, Yu X, Wang X, Song J, Yu D Brief Bioinform. 2024; 26(1).

PMID: 39692449 PMC: 11653202. DOI: 10.1093/bib/bbae658.

A meta-analysis of bulk RNA-seq datasets identifies potential biomarkers and repurposable therapeutics against Alzheimer's disease.

Lamisa A, Ahammad I, Bhattacharjee A, Hossain M, Ishtiaque A, Chowdhury Z Sci Rep. 2024; 14(1):24717.

PMID: 39433822 PMC: 11494203. DOI: 10.1038/s41598-024-75431-z.

Research progress of the CXCR4 mechanism in Alzheimer's disease.

Wang Q, Fang C, Huang X, Xue L Ibrain. 2023; 8(1):3-14.

PMID: 37786419 PMC: 10528775. DOI: 10.1002/ibra.12026.

A meta-analysis of microarray datasets to identify biological regulatory networks in Alzheimer's disease.

Hashemi K, Aliabadi M, Mehrara A, Talebi E, Hemmati A, Rezaeiye R Front Genet. 2023; 14:1225196.

PMID: 37705610 PMC: 10497115. DOI: 10.3389/fgene.2023.1225196.

References

Jander S, Schroeter M, Fischer J, Stoll G . Differential regulation of microglial keratan sulfate immunoreactivity by proinflammatory cytokines and colony-stimulating factors. Glia. 2000; 30(4):401-10. DOI: 10.1002/(sici)1098-1136(200006)30:4<401::aid-glia90>3.0.co;2-6. View

Zhao J, Deng Y, Jiang Z, Qing H . G Protein-Coupled Receptors (GPCRs) in Alzheimer's Disease: A Focus on BACE1 Related GPCRs. Front Aging Neurosci. 2016; 8:58. PMC: 4805599. DOI: 10.3389/fnagi.2016.00058. View

Harcha P, Garces P, Arredondo C, Fernandez G, Saez J, van Zundert B . Mast Cell and Astrocyte Hemichannels and Their Role in Alzheimer's Disease, ALS, and Harmful Stress Conditions. Int J Mol Sci. 2021; 22(4). PMC: 7919494. DOI: 10.3390/ijms22041924. View

Hur E, Kim K . G protein-coupled receptor signalling and cross-talk: achieving rapidity and specificity. Cell Signal. 2002; 14(5):397-405. DOI: 10.1016/s0898-6568(01)00258-3. View

Oakley H, Cole S, Logan S, Maus E, Shao P, Craft J . Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J Neurosci. 2006; 26(40):10129-40. PMC: 6674618. DOI: 10.1523/JNEUROSCI.1202-06.2006. View

Asuni A, Boutajangout A, Quartermain D, Sigurdsson E . Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci. 2007; 27(34):9115-29. PMC: 6672191. DOI: 10.1523/JNEUROSCI.2361-07.2007. View

Wahrle S, Jiang H, Parsadanian M, Kim J, Li A, Knoten A . Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008; 118(2):671-82. PMC: 2200302. DOI: 10.1172/JCI33622. View

Calsolaro V, Edison P . Neuroinflammation in Alzheimer's disease: Current evidence and future directions. Alzheimers Dement. 2016; 12(6):719-32. DOI: 10.1016/j.jalz.2016.02.010. View

Reaux-Le Goazigo A, Steenwinckel J, Rostene W, Melik Parsadaniantz S . Current status of chemokines in the adult CNS. Prog Neurobiol. 2013; 104:67-92. DOI: 10.1016/j.pneurobio.2013.02.001. View

10.

Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, Abramsky O . Repeated immunization of mice with phosphorylated-tau peptides causes neuroinflammation. Exp Neurol. 2013; 248:451-6. DOI: 10.1016/j.expneurol.2013.07.006. View

11.

Kuroda E, Takata K, Nishimura K, Oka H, Sueyoshi M, Aitani M . Peripheral Blood-Derived Microglia-Like Cells Decrease Amyloid-β Burden and Ameliorate Cognitive Impairment in a Mouse Model of Alzheimer's Disease. J Alzheimers Dis. 2019; 73(1):413-429. DOI: 10.3233/JAD-190974. View

12.

Guo T, Noble W, Hanger D . Roles of tau protein in health and disease. Acta Neuropathol. 2017; 133(5):665-704. PMC: 5390006. DOI: 10.1007/s00401-017-1707-9. View

13.

Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M . Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010; 9(7):702-16. DOI: 10.1016/S1474-4422(10)70119-8. View

14.

Donkin J, Stukas S, Hirsch-Reinshagen V, Namjoshi D, Wilkinson A, May S . ATP-binding cassette transporter A1 mediates the beneficial effects of the liver X receptor agonist GW3965 on object recognition memory and amyloid burden in amyloid precursor protein/presenilin 1 mice. J Biol Chem. 2010; 285(44):34144-54. PMC: 2962513. DOI: 10.1074/jbc.M110.108100. View

15.

Kucia M, Jankowski K, Reca R, Wysoczynski M, Bandura L, Allendorf D . CXCR4-SDF-1 signalling, locomotion, chemotaxis and adhesion. J Mol Histol. 2004; 35(3):233-45. DOI: 10.1023/b:hijo.0000032355.66152.b8. View

16.

Xu L, He D, Bai Y . Microglia-Mediated Inflammation and Neurodegenerative Disease. Mol Neurobiol. 2015; 53(10):6709-6715. DOI: 10.1007/s12035-015-9593-4. View

17.

Beck T, Gomes A, Cyster J, Pereira J . CXCR4 and a cell-extrinsic mechanism control immature B lymphocyte egress from bone marrow. J Exp Med. 2014; 211(13):2567-81. PMC: 4267240. DOI: 10.1084/jem.20140457. View

18.

Tao Y . Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther. 2008; 120(2):129-48. PMC: 2668812. DOI: 10.1016/j.pharmthera.2008.07.005. View

19.

Sanfilippo C, Castrogiovanni P, Imbesi R, Nunnari G, Di Rosa M . Postsynaptic damage and microglial activation in AD patients could be linked CXCR4/CXCL12 expression levels. Brain Res. 2020; 1749:147127. DOI: 10.1016/j.brainres.2020.147127. View

20.

Esquerda-Canals G, Montoliu-Gaya L, Guell-Bosch J, Villegas S . Mouse Models of Alzheimer's Disease. J Alzheimers Dis. 2017; 57(4):1171-1183. DOI: 10.3233/JAD-170045. View